Literature DB >> 30980147

[Insulin therapy of type 2 diabetes mellitus (Update 2019)].

Monika Lechleitner1, Martin Clodi2,3, Heidemarie Abrahamian4, Helmut Brath5, Johanna Brix6, Heinz Drexel7,8,9,10,11, Peter Fasching12, Bernhard Föger13,14, Claudia Francesconi15, Elke Fröhlich-Reiterer16, Jürgen Harreiter17, Sabine E Hofer18, Friedrich Hoppichler19, Joakim Huber20, Susanne Kaser21,22, Alexandra Kautzky-Willer23, Bernhard Ludvik6, Anton Luger17, Julia K Mader24, Bernhard Paulweber25, Thomas Pieber26, Rudolf Prager27, Birgit Rami-Merhar28, Michael Resl3, Michaela Riedl17, Michael Roden29,30,31, Christoph H Saely32, Christian Schelkshorn33, Guntram Schernthaner34, Harald Sourij24, Lars Stechemesser25, Harald Stingl35, Hermann Toplak24, Thomas C Wascher36, Raimund Weitgasser37,38, Yvonne Winhofer-Stöckl17, Sandra Zlamal-Fortunat39.   

Abstract

The present article is a recommendation of the Austrian Diabetes Association for the practical use of insulin in type 2 diabetes, including the various insulin regimens.

Entities:  

Keywords:  Insulin therapy and type 2 diabetes mellitus

Mesh：

Substances：

Year:  2019        PMID： 30980147     DOI： 10.1007/s00508-019-1492-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


  42 in total

1.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

2.  Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.

Authors:  William H Herman; John B Buse; Richard F Arakaki; Kathleen M Dungan; Honghua H Jiang; Jennie G Jacobson; Jessie L Fahrbach
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

Review 3.  Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.

Authors:  Faramarz Ismail-Beigi; Etie Moghissi; Margaret Tiktin; Irl B Hirsch; Silvio E Inzucchi; Saul Genuth
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

4.  Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Authors:  Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; Eric Renard; David Russell-Jones; Areti Philotheou; Ann Marie Ocampo Francisco; Huiling Pei; Bruce Bode
Journal:  Lancet       Date:  2012-04-21       Impact factor: 79.321

Review 5.  Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.

Authors:  Bianca Hemmingsen; Louise Lundby Christensen; Jørn Wetterslev; Allan Vaag; Christian Gluud; Søren S Lund; Thomas Almdal
Journal:  BMJ       Date:  2012-04-19

6.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.

Authors:  Matteo Monami; Niccolò Marchionni; Edoardo Mannucci
Journal:  Diabetes Res Clin Pract       Date:  2008-05-20       Impact factor: 5.602

9.  Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.

Authors:  Kitty Poon; Allen B King
Journal:  Drug Healthc Patient Saf       Date:  2010-10-28

10.  Update on insulin therapy for type 2 diabetes.

Authors:  Thomas Donner; Miguel Muñoz
Journal:  J Clin Endocrinol Metab       Date:  2012-03-22       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.